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Granulocytic Airway Inflammation and Clinical Asthma Outcomes
Prospective longitudinal studies looking at the relationship between
airway inflammation and clinical asthma outcomes in real life are
of great importance to better understand the disease and choose
appropriate treatment. The Severe Asthma Research Program III
(SARP III) is a network of U.S. investigators whose purpose is to
advance the understanding of severe asthma through integration
of mechanistic studies with detailed phenotypic and endotypic
characterization (1).
In this issue of the Journal, Hastie and colleagues (pp. 882–892)
report on the stability/instability of airway granulocytic
inflammation by analyzing induced sputum cell content over a
3-year period and relate granulocytic inflammation to clinical
outcomes such as exacerbation, day-to-day asthma control, and
lung function decline in 206 subjects with asthma, the large
majority of whom were on inhaled corticosteroids (ICS)/long-
acting b2-agonists as maintenance treatment (2). Treatment change
was left at the discretion of the investigators, but initiation of any
biologics led to exclusion of the patients. In their article, Hastie and
colleagues proposed two patient group classifications. One was
based on sputum eosinophil or neutrophil count variability,
identifying three groups as predominant low, highly variable, and
predominant high. The other was based on the combination of
low/high sputum eosinophil and neutrophil, leading to four groups
called paucigranulocytic, neutrophilic, eosinophilic, or mixed
granulocytic, as defined by Simpson and colleagues (3). The current
study brings several key results. The first important finding is that
the predominant low eosinophil group is the largest, representing
59% of the patients enrolled, whereas the highly variable and
predominant high groups accounted for 15% and 25%, respectively.
Therefore, most of the patients display a relative stability in their
eosinophilic phenotype over the follow-up. The proportion of the
predominant low eosinophil group may appear surprisingly high
in this study, which mainly focused on severe asthma compared
with a previous severe asthma cohort study (4), but it may be
overestimated because the authors have excluded patients using
biologics. However, recent real-world data have shown that
anti–IL-5 and omalizumab are generally administrated in patients
with significant increases in sputum eosinophils (5, 6).
Second, the predominant low eosinophil group shows the
highest baseline lung function, no disease progression as reflected by
change in FEV1, and the lowest exacerbation rate. The highly variable
group shows reduced expiratory flow rates with greater airway
obstruction, higher reversibility to albuterol, and the highest rate of
exacerbation despite a higher use of ICS/long-acting b2-agonists and
leukotriene receptor antagonists (Figure 1). The predominant high
eosinophil group shows equally altered expiratory flow rate, airway
obstruction, and reversibility as the highly variable group but with a
lower rate of healthcare use, which is actually comparable to the
predominant low eosinophil group. Adopting similar classification
with sputum neutrophils does not reveal any relevant disease
characteristics apart from older age in those in the predominant high
neutrophil group, which is confirmatory of previous findings (7).
The results of the current study (2) further support the role of
fluctuation of sputum eosinophil count in modifying asthma
control as it has been highlighted by Demarche and colleagues (8)
in a real-life study in which fluctuation in Asthma Control
Questionnaire six-item version was partly and independently
determined by fluctuation in sputum eosinophils and FEV1.
In Hastie’s study, the exacerbation rate was greater in the group
with high sputum eosinophil variation than in the group with
persistently high count, indicating that a temporary rise in
sputum eosinophils may be a factor for asthma exacerbation;
this finding is in agreement with the strategy of maintaining a
low level of sputum eosinophils to reduce exacerbation (9).
The current study (2) clearly demonstrates, however, that
exacerbation may happen in those patients with predominant low
sputum eosinophils, and other SARP III publications have shown
that high plasma IL-6 concentrations, which are associated with
blood neutrophilia and metabolic dysfunction and obesity (10),
were predictive of exacerbation (11). It is worth noting that the
group with high sputum neutrophil count variation was not at
greater risk of exacerbation, as opposed to the group with high
eosinophil fluctuation.
Third, in addition to asthma control and exacerbation rate, the
current study also looked at pre- and post-bronchodilation FEV1 decline
over 3 years. Overall, the changes in pre- and post-bronchodilation
FEV1 were very limited and the predominantly low and highly variable
eosinophil groups even displayed a small increase of 1–2% in pre- and
post-bronchodilation FEV1% predicted after 3 years. The airway
inflammatory pattern that was associated with the greater loss in lung
function was characterized by persistent eosinophil-high and neutrophil
high-infiltrate, which is called mixed granulocytic asthma. This
phenotype was previously associated with the most altered lung function
in another large cross-sectional study (7) (Figure 1). Hastie and
colleagues found an average loss in post-bronchodilation FEV1
between 1% and 2% predicted after 3 years. By contrast, neither
the isolated predominant high sputum eosinophil group nor the
isolated predominant high sputum neutrophil group displayed such
a loss in lung function. This would therefore suggest that it is the
interaction between eosinophils and neutrophils that enhances the
potential of airway remodeling, assuming that the latter is reflected by
progressive decline in FEV1. There are in vitro studies that
support a role for neutrophils directly or indirectly enhancing
eosinophil function, with neutrophil elastase favoring eosinophil
degranulation (12) and maturation of IL-33 (13), a potent agonist
for eosinophils. Moreover, there is in vivo evidence that airway
neutrophils may prevent ICS from delivering beneficial effects in
asthma (14). In another longitudinal study, the group with
persistent high eosinophilic airway inflammation did not show
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accelerated lung function decline but had lower sputum
neutrophil counts than the fast decliner group with highly
variable sputum eosinophils (4), further supporting the idea that
the combination of eosinophils and neutrophils is important in
lung function decline. On the other hand, the current study by
Hastie and colleagues show that healthcare use in mixed
granulocytic asthma was, however, not strikingly different from
that seen in other groups, illustrating that processes leading to
progressive lung function decline may be different from the ones
resulting in loss of control and exacerbation. Whether biologics,
which are potent at reducing exacerbation rates in subjects with
T2 severe asthma, may actually prevent the loss of lung function
in those with mixed granulocytic asthma remains to be clarified in
long-term longitudinal studies.
Finally, it is worth noting that, whichever classification is chosen,
the patients in SARP III show, over 3 years of follow-up, an
improvement in asthma control together with consistent reduction in
exacerbation, which may even approach 60% in the predominant
eosinophil low group (2). It is even more remarkable that, over the
same duration, the proportion of patients with high-dose ICS was
reduced, thereby pointing to an overdosing of ICS in real life in
many patients with asthma. There is no doubt that improved
drug adherence linked to study participation may have contributed
to this observation, but we might not exclude that a reduction in
the dosage of ICS may really be beneficial to some patients, especially
in the groups without high sputum eosinophil counts. Recent studies
focusing on noneosinophilic or non-T2 asthma have shown
maintained or improved asthma control in some patients when
stepping down ICS (15, 16). As advocated by Beasley and colleagues
(17), it is time to set a new target for asthma: for patients with
uncontrolled asthma, we should consider underlying inflammatory
phenotypes and associated comorbid traits before initiating any
systematic step-up in ICS dose. n
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www.atsjournals.org.
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Figure 1. Relationship between granulocytic airway pattern and asthma clinical outcomes. The arrow in the top right panel indicates that neutrophils may
enhance eosinophil degranulation.
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Asthma and COVID-19: Preconceptions about Predisposition
It is now just past 15 months since coronavirus disease (COVID-19)
was identified in China and rapidly spread throughout the world.
There has been an extraordinary research effort to understand
the pathophysiology of COVID-19, providing an evidence base
on which to develop public health, therapeutic, and vaccine
interventions. The burden of COVID-19 falls disproportionately on
different populations, and research has sought to rapidly identify
those at higher risk, such as those with specific comorbidities.
The situation with asthma was intriguing from the outset
of the pandemic, with initial case series either not reporting that
COVID-19 infections provoked severe exacerbations of asthma
(1, 2) or specifically reporting that patients hospitalized with
COVID-19 did not present with severe asthma exacerbations (3).
These observations were unexpected, as viral respiratory tract
infections are the most common cause of severe exacerbations
of asthma. Specifically, Coronaviridae are associated with up to 13%
of asthma exacerbations in children (4) and up to 16% in adults (5).
Whether people with asthma represented a high-risk
population came into sharp focus when chronic obstructive
pulmonary disease was strongly associated with severe disease, ICU
admission, and death (6, 7). However, a similar risk was not
identified with asthma when adjusted for other variables, although
asthma with recent oral corticosteroid use increased the risk of
mortality from COVID-19 in one study (8).
These reports were followed by a systematic review and meta-
analysis of COVID-19 studies that reported outcomes in patients
with asthma and had been published by August 18, 2020 (9).
The main findings of this review were that asthma was not
associated with higher COVID-19 severity and that patients with
asthma had a lower risk of death. Knowledge in this field has
now been extended with the publication by Terry and colleagues
(pp. 893–905) of a systematic review and meta-analysis of studies
in this issue of the Journal that examined the prevalence and/or risk
of severe disease in adult patients with asthma and COVID-19 (10).
Advantages of this current review include the availability of
considerably more studies for inclusion in the meta-analysis, the
comparison with asthma prevalence rates in the broad populations
studied, and the use of multivariate modeling in the subset of
studies of asthma and COVID-19 mortality.
First, the authors report that their findings suggest the
possibility of a moderate decreased risk of a COVID-19 diagnosis in
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